Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada |
| |
Authors: | Krahn Murray D John-Baptiste Ava Yi Qilong Doria Andrea Remis Robert S Ritvo Paul Friedman Samuel |
| |
Affiliation: | Department of Medicine, University Health Network, Department of Health Policy, Management and Evaluation, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 1C4. murray.krahn@uhn.on.ca |
| |
Abstract: | Hepatitis C virus (HCV) vaccine development remains at an early stage. We explored the economic and health consequences of potential HCV vaccines by comparing universal vaccination with a hepatitis C vaccine to no vaccination in two groups: (1) injecting drug users (IDU); (2) all 12 year olds, using a Markov cohort simulation. Among IDUs, vaccination would avert 248 cases of HCV infection and 89 HCV-related deaths per 1000 individuals, and reduce costs. In average risk cohorts, vaccination did not reduce costs but was reasonably cost effective. These results provide encouragement to vaccine developers that a vaccine that is moderately effective and reasonably priced should not face economic barriers to implementation and will be attractive to third party payers. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|